Genomadix
1 known investors
Genomadix develops the Genomadix Cube, a portable real-time qPCR molecular diagnostic platform that performs point-of-need pharmacogenetic testing, including CYP2C19 genotyping from a cheek swab with results in about an hour. It serves clinicians treating acute conditions such as stroke, TIA, and acute coronary syndrome to guide antiplatelet therapy decisions.
BiotechDigital HealthMedical Devices
Investors · 1
Frequently asked questions
- What does Genomadix do?
- Genomadix develops the Genomadix Cube, a portable real-time qPCR molecular diagnostic platform that performs point-of-need pharmacogenetic testing, including CYP2C19 genotyping from a cheek swab with results in about an hour. It serves clinicians treating acute conditions such as stroke, TIA, and acute coronary syndrome to guide antiplatelet therapy decisions.
- Who are Genomadix's investors?
- Genomadix's investors include UCeed Funds.